Literature DB >> 17417797

Significance of pleural effusion in neuroblastoma.

Himesh Gupta1, John Conrad, Joseph D Khoury, Lisa M McGregor, Matthew J Krasin, Jeffrey S Dome, Victor M Santana, Andrew M Davidoff.   

Abstract

BACKGROUND: Pleural effusion is uncommon at diagnosis of neuroblastoma in children. Because the presence of malignant cells in pleural fluid may significantly change the management and outcome of patients with neuroblastoma, we retrospectively analyzed a cohort of neuroblastoma patients who presented with pleural effusion at the time of diagnosis to determine the incidence, presentation, stage, treatment, and outcome of these patients.
METHODS: We reviewed the presenting features of 295 patients with the diagnosis of neuroblastoma who received treatment at St. Jude Children's Research Hospital between 1991 and 2005. Patients were chosen for further analysis if pleural effusion had been identified on chest radiographs or computed tomography (CT) scans at diagnosis
RESULTS: Thirty-one out of 295(10.5%) patients with neuroblastoma had pleural effusion identified at time of presentation. International neuroblastoma staging system (INSS) risk stratification was high risk in 29 cases and intermediate risk and low risk in 1 case each. The primary site of disease was abdomen in 26 patients; mediastinum in 5. We conducted cytologic analysis of pleural fluid of nine patients; the specimen of seven contained malignant cells. Eighteen of 31 patients died of progressive or recurrent disease.
CONCLUSION: In patients with neuroblastoma, pleural effusion is usually associated with unfavorable biologic features and high-risk disease. Pleural fluid should be examined cytologically and at a time when the results would change the risk stratification. There was no statistically significant difference in the survival rate of the patients with high-risk neuroblastoma with or without malignant pleural effusion. 2007 Wiley-Liss, Inc

Entities:  

Mesh:

Year:  2007        PMID: 17417797     DOI: 10.1002/pbc.21199

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.

Authors:  Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

2.  Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma.

Authors:  John Thomas Lucas; Daniel Victor Wakefield; Michael Doubrovin; Yimei Li; Teresa Santiago; Sara Michele Federico; Thomas E Merchant; Andrew M Davidoff; Matthew J Krasin; Barry L Shulkin; Victor M Santana; Wayne Lee Furman
Journal:  Clin Transl Radiat Oncol       Date:  2022-03-10

Review 3.  Serous fluid: Metastatic sarcomas, melanoma, and other non-epithelial neoplasms.

Authors:  Liron Pantanowitz; Mamatha Chivukula
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

4.  Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant effusion in children with solid tumors or lymphoma.

Authors:  Yu-Tong Zhang; Xiao-Dan Zhong; Yan-Li Gao; Jian Chang
Journal:  BMC Cancer       Date:  2021-12-06       Impact factor: 4.430

5.  Predictive factors of acute respiratory events during initial induction chemotherapy in patients with advanced neuroblastoma.

Authors:  Motohiro Matsui; Atsushi Makimoto; Nobuhiro Nishio; Yoshiyuki Takahashi; Mitsuyoshi Urashima; Yuki Yuza
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.